The combination of Tesamorelin and Ipamorelin brings together two peptides that both influence the growth-hormone axis, but through distinct biological pathways. Tesamorelin, a GHRH analog, acts directly on GHRH receptors to promote the release of endogenous growth hormone, while Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone secretion through a separate signaling mechanism. When studied together, these peptides are often evaluated for their potential to produce complementary or synergistic effects on pituitary activity and downstream IGF-1 signaling.
Research exploring this blend has examined its impact on sleep architecture, energy balance, metabolic pathways, cognitive performance, and changes in body composition. Investigators have assessed how combined stimulation of the growth-hormone axis may influence lipid regulation, visceral adipose tissue, inflammatory markers, cardiovascular indicators such as carotid intima-media thickness, and other metabolic functions. The pair is also studied in contexts involving muscle growth, lean body mass maintenance, and the optimization of natural growth-hormone rhythms.
COAs: Blends are combinations of the following peptides. View certificate of analysis on the product pages for Ipamorelin and Tesamorelin.
Disclaimer: This peptide is for research and educational purposes only.


